Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
More studies should validate whether intracranial pressure-reducing drugs, GLP-1s included, can be a new target for migraine relief, the researchers say
In a 36-week Phase 1b/2a trial, participants receiving 60mg weekly of Amycretin reported body weight reductions of up to 24.3% versus 1.1% with placebo after 36 weeks of treatment
This increases fullness, decreases appetite, and reduces caloric intake, thereby leading to modest weight loss
Aliabadi says
It says the data is insufficient and that animal studies suggest potential risk
US$ 28.33
US$ 28.38
US$ 23.23
US$ 27.13
US$ 27.94
US$ 22.91
